Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-18
    E.g., 2018-11-18



14756 items
5:14 PM, Nov 15, 2018  |  BC Innovations | Emerging Company Profile

Virion: Harnessing viral defects

Virion Biotherapeutics Ltd. has capitalized on a naturally occurring viral mutation to develop broad-spectrum antivirals with lower potential for resistance than marketed products. Its lead compound, VH244, is in preclinical development to treat respiratory infections...
2:55 PM, Nov 15, 2018  |  BC Innovations | Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
2:43 PM, Nov 15, 2018  |  BC Innovations | Tools & Techniques

Benchtop manufacturing gets smaller

MIT scientists continue to break new ground in benchtop manufacturing systems for biologics. Published in Nature Biotechnology last month, the latest advance from the institute centered on an automated, closed system capable of producing clinical-grade...
2:33 PM, Nov 15, 2018  |  BC Innovations | Translation in Brief

The bystander effect of Treg depletion

Limiting bystander effects of immunosuppressive Treg-targeting therapies may be crucial for their antitumor efficacy, according to data released last week at the Society for Immunotherapy of Cancer meeting. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) presented...
3:58 PM, Nov 14, 2018  |  BC Innovations | Translation in Brief

Gene therapy rising

Ophthotech Corp. (NASDAQ:OPHT) closed its third gene therapy-focused public-private partnership of the year on Oct. 31, and is one of more than a dozen companies that have licensed preclinical gene therapies this year from academics....
2:51 PM, Nov 13, 2018  |  BC Innovations | Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts miR-378-deficient mice could be used to screen therapies for muscular dystrophy. Mice with miR-378 knocked out recapitulated the low muscle weight, poor motor performance, defects in autophagy, mitochondrial abnormalities and skeletal muscle...
2:50 PM, Nov 13, 2018  |  BC Innovations | Distillery Therapeutics


INDICATION: B cell lymphoma Cell and mouse studies suggest promoting PMAIP1 expression or inhibiting MCL1 could enhance the efficacy of BCL-2 inhibitors to treat diffuse large B cell lymphoma (DLBCL). In a DLBCL cell line,...
2:50 PM, Nov 13, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Enterovirus In vitro, cell culture and mouse studies identified two iminooxazolidin-based inhibitors of Enterovirus 3C protease that could help treat Enterovirus 71 infection. Optimization and testing of a previously reported cyanohydrin-based Enterovirus 3C protease inhibitor...
2:50 PM, Nov 13, 2018  |  BC Innovations | Distillery Therapeutics


INDICATION: Asthma In vitro and rat studies identified a pyrrolopyrimidine-based PI3Kδ inhibitor that could help treat asthma. Chemical synthesis and in vitro binding assays of pyrrolopyrimidine analogs yielded a compound that inhibited PI3Kδ with an...
10:51 AM, Nov 13, 2018  |  BC Innovations | Distillery Therapeutics


INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting HDAC3 could help treat AD. In a HEK cell line expressing mutant APP, a tool compound HDAC3 inhibitor decreased levels of neurotoxic β amyloid compared...